Highlights from American Diabetes Association (ADA) 2026 Scientific Sessions

Click on the tabs below to watch videos from the ADA 2026 Scientific Sessions.

Highlights from ADA 2026 Scientific Sessions

Join us as we bring you the latest highlights from the American Diabetes Association (ADA) 2026 Scientific Sessions in New Orleans, LA, USA, taking place 5-8 June 2026!
Supported by an unrestricted educational grant from AstraZeneca, Boehringer Ingelheim, Lilly and Novo Nordisk.

Click on the tabs below to watch videos from the ADA 2026 Scientific Sessions. Explore key highlights and the latest updates on the SYNCHRONIZE, TRANSCEND, TRIUMPH, REIMAGINE and ACHIEVE trials.

Highlights from ADA 2026 Scientific Sessions

Boris Kovatchev

AI Models in Fully Closed Loop

Sean Wharton

Treating Osteoarthritis with Obesity Medications

Carel le Roux

Amylin as a Novel Diabetes and Obesity Therapy

Jonathan Shaw

Dual Agonism in Type 1 Diabetes: Unveiling Efficacy and Safety of Adjunct Therapy with CT-868 (GLP-1/GIP RA) in Adults with Type 1 Diabetes – Phase 1 and 2 Results

Sof Andrikopoulos

The VESPER-1 OLE, -2 and -3 Trials of Berobenatide (MET-097, PF-08653944) an Ultra-Long-Acting GLP-1 Receptor Agonist for Weight Management

Arianne Sweeting

Glycemic Observation and Metabolic Outcomes in Mothers and Offspring (GO MOMs) Study

Martin Haluzík

ACCESS Trial: Dose-Ranging Evaluation of Aleniglipron, an Oral Small Molecule Nonpeptide GLP-1RA, Demonstrates Meaningful Weight Reductions in People Living with Obesity and Overweight

Lee-Ling Lim

Lancet Journal Symposium: Cardiometabolic Multiple Long-Term Conditions (Multimorbidity) – Epidemiology, Mechanisms, Models, and Management

David Simmons

Summary of Gestational Diabetes Sessions

Melkam Kebede

Discussion on Islet Biology, Development, and Function: Small, but Mighty – Extra Islet Beta-Cells are Preserved or Lost in Type 1 Diabetes?

Melkam Kebede

Molecular and Therapeutic Strategies for Diabetes

Dianna Magliano

Innovation in Diabetes

Tim Dall

Economic Cost of Treating vs. Not Treating

Yao Qin

AI for Automatic Nutrition Estimation

Soo-Heon Kwak

Dual Agonism in Type 1 Diabetes: Unveiling Efficacy and Safety of Adjunct Therapy with CT-868 (GLP-1/GIP RA) in Adults with Type 1 Diabetes – Phase 1 and 2 Results

Soo-Heon Kwak

Glycemic Observation and Metabolic Outcomes in Mothers and Offspring (GO MOMs) Study

Soo-Heon Kwak

Genetics of Diabetes

Text

Text

Text

Text

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.

SYNCHRONIZE Trial

Matthias Tschöp

Why Was Glucagon Chosen for Metabolic Benefit?

Carel le Roux

The Benefits of Glucagon/GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE Phase 3 Studies of Survodutide

Lee Kaplan

Design and Outcomes of SYNCHRONIZE-MASLD: Survodutide for the Treatment of Obesity and MASLD

Jaime Almandoz

The Clinical Implications of Glucagon/GLP-1 Receptor Dual Activation for the Treatment of Obesity and Steatotic Liver Disease

Martin Haluzík

The Benefits of Glucagon/GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE Phase 3 Studies of Survodutide

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.

TRANSCEND and TRIUMPH Trials

Jonathan Campbell

What Does Glucagon Receptor Agonism Add to the Effects of GIP and GLP-1 Receptor Agonism?

Harpreet Bajaj

Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in Patients with T2D (TRANSCEND-T2D-1)

Ania Jastreboff

Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in Patients with Obesity (TRIUMPH-1)

Jonathan Shaw

Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in Patients with Obesity (TRIUMPH-1)

The ADS gratefully acknowledges the support from Novo Nordisk for the STEP UP Trial videos.

STEP UP Articles:

REIMAGINE Trial

Vanita Aroda

REIMAGINE 1: CagriSema as Monotherapy for Drug-Naïve T2D

Akshay Jain

REIMAGINE 2: CagriSema vs. Semaglutide or Cagrilintide in T2D on Metformin ± SGLT2i

Julio Rosenstock

REIMAGINE 3: CagriSema Add-On for Basal Insulin-Treated T2D ± Metformin

The ADS gratefully acknowledges the support from Novo Nordisk for the STEP UP Trial videos.

STEP UP Articles:

ACHIEVE Trial

Sof Andrikopoulos

Orforglipron Compared with Dapagliflozin in Type 2 Diabetes: Results from ACHIEVE-2

Julio Rosenstock

Orforglipron Compared with Oral Semaglutide in Type 2 Diabetes: Results from ACHIEVE-3

Francesco Giorgino

Orforglipron Compared with Placebo as an Add-On to Titrated Insulin Glargine: Results from ACHIEVE-5

Alice Cheng

ACHIEVE-ing Goals: Where Do Nonpeptide Oral GLP-1 Receptor Agonists Fit in the Treatment Algorithm?

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.

Introduction

Josephine Forbes

Introduction

Sof Andrikopoulos

Welcome to EASD

Chantal Mathieu

President of EASD | Summary of the EASD 2025, looking ahead to EASD 2026

STEP UP Articles:

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.

The ADS gratefully acknowledges the support from Novo Nordisk for the STEP UP Trial videos.

Click the buttons to view other highlights from the EASD Annual Meeting 2025.

Highlights will be available at the end of the conference. Stay tuned!

Day 4

Day 4 highlights will be available soon. Stay tuned!

TBC